Bank of New York Mellon’s Lisata Therapeutics LSTA Stock Holding History

Bank of New York Mellon’s Portfolio LSTA Stock Details LSTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-557	Closed	-$50K	–	4298
2016 Q2	$50K	Buy	557 +7	+1%	+$644	﹤0.01%	4173
2016 Q1	$62K	Sell	550 -177	-24%	-$17.4K	﹤0.01%	4053
2015 Q4	$118K	Buy	727 +20	+3%	+$3.67K	﹤0.01%	4019
2015 Q3	$158K	Buy	707 +140	+25%	+$35.1K	﹤0.01%	3980
2015 Q2	$158K	Sell	567 -403	-42%	-$150K	﹤0.01%	3940
2015 Q1	$370K	Hold	970	–	–	﹤0.01%	3719
2014 Q4	$548K	Sell	970 -10	-1%	-$6.81K	﹤0.01%	3581
2014 Q3	$812K	Hold	980	–	–	﹤0.01%	3407
2014 Q2	$959K	Buy	980 +460	+88%	+$447K	﹤0.01%	3333
2014 Q1	$550K	Hold	520	–	–	﹤0.01%	3558
2013 Q4	$532K	Buy	520 +149	+40%	+$147K	﹤0.01%	3569
2013 Q3	$475K	Buy	+371	New	+$412K	﹤0.01%	3544

Other funds holding LSTA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Hollencrest Capital Management Newport Beach, California $2.7B AUM 23.62% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EGA

Eagle Global Advisors Houston, Texas $3.02B AUM 34.37% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Bank of New York Mellon's LSTA Position: Q3 2016 in Review

Bank of New York Mellon sold out of Lisata Therapeutics (LSTA) in Q3 2016, closing a stake of 557 shares — an estimated $50K sold.

Bank of New York Mellon first reported a position in LSTA in Q3 2013 and held it in 12 quarters. The position peaked at $959K in Q2 2014. 28 funds tracked by Wall St. Rank hold LSTA as of Q3 2016.

Bank of New York Mellon reported no remaining Lisata Therapeutics position as of Q3 2016 after selling out during the quarter.
Bank of New York Mellon sold 557 Lisata Therapeutics shares in Q3 2016, an estimated $50K.
Bank of New York Mellon first reported a position in Lisata Therapeutics in Q3 2013 and held it in 12 quarters.
Bank of New York Mellon's Lisata Therapeutics position peaked at $959K in Q2 2014.
28 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q3 2016.

Based on Bank of New York Mellon's 13F filing for Q3 2016, filed 3 Nov 2016.